PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth
PRDM16 initiates a dormancy program in prostate cancer cells that is sustained in the bone marrow microenvironment, highlighting PRDM16 as a potential biomarker for relapse and target for eliminating dormant cancer cells.
Authors
- Conor C. Lynch (ORCID: https://orcid.org/0000-0002-4506-6244)
- Marilena Tauro (ORCID: https://orcid.org/0000-0003-2361-7364)
- Jeremy S. Frieling (ORCID: https://orcid.org/0000-0002-2181-1836)
- Haley du Bois (ORCID: https://orcid.org/0000-0002-2754-9971)
- Bishoy Wadie (ORCID: https://orcid.org/0000-0001-8692-1107)
- Ryan T. Bishop (ORCID: https://orcid.org/0000-0002-1332-4798)
- Tao Li (ORCID: https://orcid.org/0000-0002-2681-0429)
- Kathryn Nyman (ORCID: https://orcid.org/0000-0002-3806-1031)
- Mostafa Nasr (ORCID: https://orcid.org/0000-0001-7834-6384)
- B. S. Malik
Institutions
- University of South Florida (US)
- Moffitt Cancer Center (US)
- European Molecular Biology Laboratory (DE)
- European Molecular Biology Laboratory (DE)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1158/0008-5472.can-24-4809
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04